The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study

References

• MartinPJ, InamotoY, FlowersME, CarpenterPA. Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant. 2012;18(7):982–988. doi:10.1016/j.bbmt.2012.04.00622510383
   PubMed Web of Science ®Google Scholar
• BacigalupoA. Management of acute graft-versus-host disease. Br J Haematol. 2007;137(2):87–98. doi:10.1111/j.1365-2141.2007.06533.x17391488
   PubMed Web of Science ®Google Scholar
• SpoerlS, MathewNR, BscheiderM, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–3842. doi:10.1182/blood-2013-12-54373624711661
   PubMed Web of Science ®Google Scholar
• ZeiserR, BurchertA, LengerkeC, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–2068. doi:10.1038/leu.2015.21226228813
   PubMed Web of Science ®Google Scholar
• FerreiraAM, PontesDSC, PereiraAD, et al. Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. Bone Marrow Transplant. 2018;53(4):503–506. doi:10.1038/s41409-017-0068-229330403
   PubMed Web of Science ®Google Scholar
• ChoiJ, ZigaED, RitcheyJ, et al. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120(19):4093–4103. doi:10.1182/blood-2012-01-40319622972985
   PubMed Web of Science ®Google Scholar
• PrzepiorkaD, LuoL, SubramaniamS, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25(2):e328–e334. doi:10.1634/theoncologist.2019-062732043777
   PubMed Web of Science ®Google Scholar
• KhandelwalP, Teusink-CrossA, DaviesSM, et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2017;23(7):1122–1127. doi:10.1016/j.bbmt.2017.03.02928344057
   PubMed Web of Science ®Google Scholar
• González VicentM, MolinaB, González de PabloJ, CastilloA, DíazMÁ. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results. Am J Hematol. 2019;94(3):319–326. doi:10.1002/ajh.2537630536806
   PubMed Web of Science ®Google Scholar
• PrzepiorkaD, WeisdorfD, MartinP, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.7581076
   PubMed Web of Science ®Google Scholar
• JagasiaMH, GreinixHD, AroraM, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401. doi:10.1016/j.bbmt.2014.12.00125529383
   PubMed Web of Science ®Google Scholar
• LeeSJ, WolffD, KitkoC, et al. Measuring therapeutic response in chronic graft-versus-host disease. national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report. Biol Blood Marrow Transplant. 2015;21(6):984–999. doi:10.1016/j.bbmt.2015.02.02525796139
   PubMed Web of Science ®Google Scholar
• HoVT, CutlerC, CarterS, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic micmangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571–575. doi:10.1016/j.bbmt.2005.06.00116041306
   PubMed Web of Science ®Google Scholar
• HodaD, PidalaJ, Salgado-VilaN, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010;45(8):1347–1351. doi:10.1038/bmt.2009.34319966849
   PubMed Web of Science ®Google Scholar
• FurlongT, MartinP, FlowersME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant. 2009;44(11):739–748. doi:10.1038/bmt.2009.7619377515
   PubMed Web of Science ®Google Scholar
• RudolphJ, HeineA, QuastT, et al. The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. Leukemia. 2016;30(10):2119–2123. doi:10.1038/leu.2016.15527220666
   PubMed Web of Science ®Google Scholar
• ChoiJ, CooperML, AlahmariB, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9(10):e109799. doi:10.1371/journal.pone.010979925289677
   PubMed Web of Science ®Google Scholar
• CarnitiC, GimondiS, VendraminA, et al. Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin Cancer Res. 2015;21(16):3740–3749. doi:10.1158/1078-0432.CCR-14-275825977345
   PubMed Web of Science ®Google Scholar
• KhouryHJ, LangstonAA, KotaVK, et al. Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant. 2018;53(7):826–831. doi:10.1038/s41409-017-0081-529367708
   PubMed Web of Science ®Google Scholar
• ShiX, YanY. Clinical observation on effect of Ruxolitinib as salvage therapy on steroid-refractory graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. J China Pediatr Blood Cancer. 2018;23(4):211–224.
   Google Scholar
• JagasiaM, ZeiserR, ArbushitesM, DelaiteP, GadbawB, BubnoffNV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018;10(5):391–402. doi:10.2217/imt-2017-015629316837
   PubMed Web of Science ®Google Scholar
• JagasiaM, PeralesMA, SchroederMA, et al. Results from REACH1, a single-arm Phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease. Blood. 2018;132(Suppl 1):601. doi:10.1182/blood-2018-99-116342
   Web of Science ®Google Scholar
• ZeiserR, BubnoffN, ButlerJ, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800–1810. doi:10.1056/NEJMoa191763532320566
   PubMed Web of Science ®Google Scholar
• NeumannT, SchneidewindL, WeigelM, et al. Ruxolitinib for therapy of graft-versus-host disease. Biomed Res Int. 2019;2019:8163780. doi:10.1155/2019/816378030956985
   PubMed Web of Science ®Google Scholar
• LohML, TasianSK, RabinKR, et al. A Phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children’s Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015;62(10):1717–1724. doi:10.1002/pbc.2557525976292
   PubMed Web of Science ®Google Scholar
• JinJ, DuX, ZhouDB, et al. Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202. Zhonghua Xue Ye Xue Za Zhi. 2016;37(10):858–863. doi:10.3760/cma.j.issn.0253-2727.2016.10.00727801315
   PubMedGoogle Scholar
• StavrouE, LazarusHM. Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr J Hematol Infect Dis. 2010;2(3):e2010033. doi:10.4084/mjhid.2010.03321776339
   PubMedGoogle Scholar
• LaskinBL, GoebelJ, DaviesSM, et al. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011;118(6):1452–1462. doi:10.1182/blood-2011-02-32131521596850
   PubMed Web of Science ®Google Scholar
• RosenthalJ. Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. J Blood Med. 2016;7:181–186. doi:10.2147/JBM.S10223527621680
   PubMedGoogle Scholar
• ZhaoY, ShiJ, LuoY, et al. Calcineurin inhibitors replacement by ruxolitinib as graft-versus-host disease prophylaxis for patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(5):e128–e133. doi:10.1016/j.bbmt.2020.01.01231982545
   PubMed Web of Science ®Google Scholar
• OnishiC, OhashiK, SawadaT, et al. A high risk of lifethreatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. Int J Hematol. 2010;91(3):464–470. doi:10.1007/s12185-010-0516-x20217287
   PubMed Web of Science ®Google Scholar
• AbedinS, McKennaE, ChhabraS, et al. Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;S1083-8791(19) 30226–5.
   Web of Science ®Google Scholar
• WatsonAP, BrunsteinCG, HoltanSG. Life-threatening hypertriglyceridemia in a patient on ruxolitinib and sirolimus for chronic graft-versus-host disease. Case Rep Transplant. 2018;2018:4539757. doi:10.1155/2018/453975730519495
   PubMedGoogle Scholar
• SatakeA, SchmidtAM, NomuraS. Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation. PLoS One. 2014;9(3):e92888. doi:10.1371/journal.pone.009288824658577
   PubMed Web of Science ®Google Scholar
• SchroederMA, KhouryHJ, JagasiaM, et al. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv. 2020;4(8):1656–1669. doi:10.1182/bloodadvances.201900104332324888
   PubMed Web of Science ®Google Scholar